Free Trial

Invivyd (IVVD) Competitors

Invivyd logo
$0.74 -0.01 (-0.93%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$0.74 +0.00 (+0.47%)
As of 07/11/2025 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IVVD vs. AMRN, PRTA, BNTC, HRTX, SNDL, VOR, AURA, ATXS, AVTE, and AVIR

Should you be buying Invivyd stock or one of its competitors? The main competitors of Invivyd include Amarin (AMRN), Prothena (PRTA), Benitec Biopharma (BNTC), Heron Therapeutics (HRTX), SNDL (SNDL), Vor Biopharma (VOR), Aura Biosciences (AURA), Astria Therapeutics (ATXS), Aerovate Therapeutics (AVTE), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry.

Invivyd vs. Its Competitors

Amarin (NASDAQ:AMRN) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

22.3% of Amarin shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 3.3% of Amarin shares are owned by company insiders. Comparatively, 25.4% of Invivyd shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Amarin has higher revenue and earnings than Invivyd. Amarin is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarin$228.61M1.53-$82.18M-$3.64-4.65
Invivyd$25.38M3.49-$169.93M-$1.20-0.62

Amarin presently has a consensus price target of $12.00, indicating a potential downside of 29.12%. Invivyd has a consensus price target of $5.85, indicating a potential upside of 692.15%. Given Invivyd's stronger consensus rating and higher probable upside, analysts plainly believe Invivyd is more favorable than Amarin.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amarin
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Invivyd
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25

In the previous week, Amarin had 1 more articles in the media than Invivyd. MarketBeat recorded 3 mentions for Amarin and 2 mentions for Invivyd. Amarin's average media sentiment score of 1.32 beat Invivyd's score of 0.93 indicating that Amarin is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amarin
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Invivyd
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Amarin has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500.

Amarin has a net margin of -41.07% compared to Invivyd's net margin of -389.01%. Amarin's return on equity of -17.21% beat Invivyd's return on equity.

Company Net Margins Return on Equity Return on Assets
Amarin-41.07% -17.21% -12.16%
Invivyd -389.01%-165.24%-99.71%

Summary

Invivyd beats Amarin on 9 of the 17 factors compared between the two stocks.

Get Invivyd News Delivered to You Automatically

Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IVVD vs. The Competition

MetricInvivydMED IndustryMedical SectorNASDAQ Exchange
Market Cap$89.42M$2.99B$5.60B$9.11B
Dividend YieldN/A2.39%5.24%4.02%
P/E Ratio-0.6220.5827.9620.25
Price / Sales3.49291.28430.5799.61
Price / CashN/A42.8637.4658.16
Price / Book1.327.638.045.49
Net Income-$169.93M-$55.05M$3.18B$250.27M
7 Day Performance-1.93%8.39%3.63%4.75%
1 Month Performance-12.79%5.35%4.04%7.64%
1 Year Performance-37.94%1.95%29.56%16.34%

Invivyd Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IVVD
Invivyd
3.4644 of 5 stars
$0.74
-0.9%
$5.85
+692.1%
-36.9%$89.42M$25.38M-0.62100
AMRN
Amarin
0.4384 of 5 stars
$16.65
-0.5%
$12.00
-27.9%
+13.5%$346.43M$228.61M-4.57360Negative News
PRTA
Prothena
3.5681 of 5 stars
$6.29
-2.2%
$31.50
+400.8%
-71.4%$346.38M$135.16M-3.02130
BNTC
Benitec Biopharma
1.7675 of 5 stars
$13.49
+2.4%
$23.83
+76.7%
+34.7%$345.72M$80K-8.9320High Trading Volume
HRTX
Heron Therapeutics
3.682 of 5 stars
$2.15
-2.3%
$5.00
+132.6%
-34.1%$335.64M$144.29M-35.83300Gap Down
SNDL
SNDL
3.0444 of 5 stars
$1.24
-2.4%
$3.63
+192.3%
-36.2%$333.73M$671.81M-4.282,516News Coverage
VOR
Vor Biopharma
3.9152 of 5 stars
$2.67
+39.8%
$5.63
+110.8%
+155.2%$333.64MN/A-1.62140Options Volume
High Trading Volume
AURA
Aura Biosciences
2.579 of 5 stars
$6.16
-6.1%
$22.00
+257.1%
-22.7%$329.76MN/A0.0050
ATXS
Astria Therapeutics
1.7593 of 5 stars
$6.20
+6.7%
$30.00
+383.9%
-43.4%$327.88MN/A-3.3230
AVTE
Aerovate Therapeutics
N/A$11.14
+3.1%
N/A-84.0%$322.89MN/A-3.7320High Trading Volume
AVIR
Atea Pharmaceuticals
2.7315 of 5 stars
$3.64
-2.7%
$6.00
+64.8%
+8.9%$320.07MN/A-2.2170News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:IVVD) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners